CRISPR Therapeutics AG (CRSP)

CRISPR Therapeutics AG's Q·Score is 5.9/10 (Neutral), reflecting its current fundamentals, analyst data, and valuation metrics. Clean balance sheet with low leverage (0.4× debt-to-equity). Key area to monitor: low return on equity (-31%). This is an informational data summary only and does not constitute financial advice. Always do your own research before making any investment decision.

The consensus price target for CRSP is $83.52, based on ratings from 21 Wall Street analysts. This is 56.4% above the current price of $53.39. Price targets are forward-looking estimates and not guarantees of future performance.

CRISPR Therapeutics AG (CRSP) scores in line with sector averages on valuation metrics. The consensus analyst price target of $83.52 is 56% above the current price.

CRISPR Therapeutics AG has a net profit margin of 0.0%, indicating the company is currently operating at a net loss. Its gross margin stands at 0.0%, reflecting a more cost-intensive business model.

CRISPR Therapeutics AG is reporting strong year-over-year growth of 68.6%.

CRISPR Therapeutics AG has a debt-to-equity ratio of 0.43×, reflecting a moderate debt level, which is manageable for most profitable companies. Its current ratio is 17.96×, indicating comfortable short-term liquidity.